Innovation and Progress

1992-1999: Discovery & Development

1992	Invention of CID by David Spencer and Gerald Crabtree (Stanford), and Stuart Schreiber (Harvard); published in Science
1994	Stanford licenses CID intellectual property to ARIAD Gene therapeutics, Inc
1995	First demonstration of CID-regulated iFAS suicide switch, and first demonstration of use in vivo in transgenic mice
1996	ARIAD designs fully synthetic, high specificity dimerizers, including AP1903 (for clinical use) and AP20187 (ARGENT^® technology, for research use, later licensed to >1,000 research groups worldwide)
1998	The year of iCaspase: papers published by four independent research groups (Spencer, Dixit, Baltimore and Lenardo)
1999	First iCaspase9 paper published (precursor to CaspaCIDe™)

2000	ARIAD sponsors AP1903 phase I clinical trial
2003	Invention of inducible CD40 (iCD40) (precursor to DeCIDe™) by David Spencer, Kevin Slawin and colleagues (Baylor College of Medicine)
2004	Bellicum founded based on iCD40 intellectual property
2005	First demonstration that iCaspase9 can be used to efficiently eliminate primary T cells in vivo with little (if any) effect on T cell function
2006	Bellicum and ARIAD execute first clinical license for CID intellectual property
2006	First closing of angel financing
2007	Invention of inducible MyD88 (iTLR) costimulatory molecule by David Spencer and colleagues, subsequently licensed by Baylor to Bellicum
2007	Bellicum receives $1.45 million award from Texas Emerging Technology Fund
2008	BPX-101 IND allowed by FDA
2009	Series A financing completed
2009	Initiation of Phase I/II clinical trial (BP-PC-001) of BPX-101 + AP1903
2009	Initiation of Phase I clinical trial (CASPALLO) of iCaspase9 by Malcolm Brenner (Baylor Center for Cell & Gene Therapy)
2010	Interim results of BP-PC-001 trial presented at AACR
2010	Interim results of CASPALLO trial presented at ASGT
2010	Demonstration of iCaspase9 functionality in mesenchymal stem cells